|
|
肺腺癌伴KIF5B-RET突变牙龈转移1例报道及文献综述
|
Abstract:
肺癌为常见肿瘤之一，晚期患者出现多发转移，但牙龈转移相对罕见，晚期以全身治疗为主，根据分子检测驱动基因选择靶向药物治疗。本文报道一例肺腺癌伴KIF5B-RET突变牙龈转移病例。
Lung cancer is one of the common tumors, with multiple metastases in late-stage patients, but gingival metastases are relatively rare. In the late stage, systemic treatment is mainly used, and targeted drug therapy is selected based on molecular detection of driving genes. This article reports a case of gingival metastasis of lung adenocarcinoma with KIF5B RET mutation.
| [1] | 郑荣寿, 陈茹, 韩冰峰, 等. 2022年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2024, 46(3): 221-231. |
| [2] | Hirshberg, A., Shnaiderman-Shapiro, A., Kaplan, I. and Berger, R. (2008) Metastatic Tumours to the Oral Cavity—Pathogenesis and Analysis of 673 Cases. Oral Oncology, 44, 743-752. https://doi.org/10.1016/j.oraloncology.2007.09.012 |
| [3] | Lopes, A.M., Freitas, F., Vilares, M. and Caramês, J. (2023) Metastasis of Malignant Tumors to the Oral Cavity: Systematic Review of Case Reports and Case Series. Journal of Stomatology, Oral and Maxillofacial Surgery, 124, Article ID: 101330. https://doi.org/10.1016/j.jormas.2022.11.006 |
| [4] | Capodiferro, S., d’Amati, A., Barile, G., Dell’Olio, F., Limongelli, L., Tempesta, A., et al. (2023) Metastatic Lung Cancer to the Head and Neck: A Clinico-Pathological Study on 21 Cases with Narrative Review of the Literature. Journal of Clinical Medicine, 12, Article No. 1429. https://doi.org/10.3390/jcm12041429 |
| [5] | Manjunatha, B. and Kumar, G. (2013) Metastatic Tumors to the Jaws and Oral Cavity. Journal of Oral and Maxillofacial Pathology, 17, 71-75. https://doi.org/10.4103/0973-029x.110737 |
| [6] | Allon, I., Pessing, A., Kaplan, I., Allon, D.M. and Hirshberg, A. (2014) Metastatic Tumors to the Gingiva and the Presence of Teeth as a Contributing Factor: A Literature Analysis. Journal of Periodontology, 85, 132-139. https://doi.org/10.1902/jop.2013.130118 |
| [7] | Gupta, S., Jawanda, M., Kedia, N., Deb, A., Ganganna, A., Saurabh, K., et al. (2022) Lung Cancer Metastasis to Oral Soft Tissues; Systematic Review of 122 Cases. Journal of Clinical and Experimental Dentistry, 14, e854-e874. https://doi.org/10.4317/jced.59773 |
| [8] | 雷艳文, 丁广成, 张剑, 等. 肝细胞癌牙龈转移1例及分析[J]. 实用老年医学, 2023, 37(2): 209-210. |
| [9] | 刘雪萍, 木乃, 李晓春, 等. 肝癌伴上下牙龈多发转移1例[J]. 中国癌症杂志, 2023, 33(1): 78-80. |
| [10] | 陈秋池, 丁然然, 雷萍, 等. 结肠腺癌转移至牙龈1例报道及文献复习[J]. 肿瘤防治研究, 2022, 49(4): 370-372. |
| [11] | 苏培培, 刘飞, 孙萍. 胃食管结合部腺癌牙龈转移1例报道[J]. 河南医学研究, 2021, 30(1): 186-188. |
| [12] | 佘杨杨, 林义佳, 刘志勇, 等. 直肠腺癌转移至牙龈1例报告及文献复习[J]. 中国口腔颌面外科杂志, 2020, 18(4): 381-384. |
| [13] | Aldea, M., Marinello, A., Duruisseaux, M., Zrafi, W., Conci, N., Massa, G., et al. (2023) RET-MAP: An International Multicenter Study on Clinicobiologic Features and Treatment Response in Patients with Lung Cancer Harboring a RET Fusion. Journal of Thoracic Oncology, 18, 576-586. https://doi.org/10.1016/j.jtho.2022.12.018 |
| [14] | Drilon, A., Rekhtman, N., Arcila, M., Wang, L., Ni, A., Albano, M., et al. (2016) Cabozantinib in Patients with Advanced RET-Rearranged Non-Small-Cell Lung Cancer: An Open-Label, Single-Centre, Phase 2, Single-Arm Trial. The Lancet Oncology, 17, 1653-1660. https://doi.org/10.1016/s1470-2045(16)30562-9 |
| [15] | Sun, L., Marmarelis, M. and Aggarwal, C. (2023) Re-Evaluating Real-World Evidence in RET Fusion-Positive NSCLC: Are Randomized Clinical Trials Needed? Journal of Thoracic Oncology, 18, 549-551. https://doi.org/10.1016/j.jtho.2023.02.001 |
| [16] | Offin, M., Guo, R., Wu, S.L., Sabari, J., Land, J.D., Ni, A., et al. (2019) Immunophenotype and Response to Immunotherapy of ret-Rearranged Lung Cancers. JCO Precision Oncology, 3, 1-8. https://doi.org/10.1200/po.18.00386 |
| [17] | Zhou, C., Solomon, B., Loong, H.H., Park, K., Pérol, M., Arriola, E., et al. (2023) First-Line Selpercatinib or Chemotherapy and Pembrolizumab in ret Fusion-Positive NSCLC. New England Journal of Medicine, 389, 1839-1850. https://doi.org/10.1056/nejmoa2309457 |
| [18] | Griesinger, F., Curigliano, G., Thomas, M., Subbiah, V., Baik, C.S., Tan, D.S.W., et al. (2022) Safety and Efficacy of Pralsetinib in RET Fusion-Positive Non-Small-Cell Lung Cancer Including as First-Line Therapy: Update from the ARROW Trial. Annals of Oncology, 33, 1168-1178. https://doi.org/10.1016/j.annonc.2022.08.002 |
